Table 2 The treatment response of 78 patients receiving bevacizumab as recurrence therapy
RT group | No. of patients, n (%) | CR, n (%) | PR, n (%) | ORR, n (%) | SD, n (%) | PD, n (%) |
|---|---|---|---|---|---|---|
78(100) | 1(1.3) | 41(52.6) | 42(53.8) | 11(14.1) | 25(32.1) | |
Platinum sensitivity | ||||||
Sensitive | 37(47.4) | 1(2.7) | 25(67.6) | 26(70.3) | 3(8.1) | 8(21.6) |
Resistant | 41(52.6) | 0(0) | 16(39.0) | 16(39.0) | 8(19.5) | 17(41.5) |
Number of previous lines of chemotherapy | ||||||
< 3 | 32(41) | 0(0) | 24(75) | 24(75) | 4(12.5) | 4(12.5) |
≥ 3 | 46(59) | 1(2.2) | 17(37.0) | 18(39.1) | 7(15.2) | 21(45.7) |